Immunological pathogenesis and treatment of systemic lupus erythematosus
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2019/02/22
-
Journal
-
Indian UGC (journal)
-
Refrences64
-
Citations171
-
Lu Pan
-
Mei-Ping Lu
-
Jing-Hua Wang
-
Meng Xu
-
Si-Rui Yang ORCID (unauthenticated)
Cite
Pan, Lu, et al. “Immunological Pathogenesis and Treatment of Systemic Lupus Erythematosus”. World Journal of Pediatrics, vol. 16, no. 1, 2019, pp. 19-30, https://doi.org/10.1007/s12519-019-00229-3.
Pan, L., Lu, M.-P., Wang, J.-H., Xu, M., & Yang, S.-R. (2019). Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics, 16(1), 19-30. https://doi.org/10.1007/s12519-019-00229-3
Pan, Lu, Mei-Ping Lu, Jing-Hua Wang, Meng Xu, and Si-Rui Yang. “Immunological Pathogenesis and Treatment of Systemic Lupus Erythematosus”. World Journal of Pediatrics 16, no. 1 (2019): 19-30. https://doi.org/10.1007/s12519-019-00229-3.
Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World Journal of Pediatrics. 2019;16(1):19-30.
Journal Categories
Medicine
Medicine (General)
Medicine
Pediatrics
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus | Frontiers in Immunology |
| 147 | 2018 |
| Nucleosomes and neutrophil extracellular traps in septic and burn patients | Clinical Immunology |
| 31 | 2017 |
| NETosis: At the crossroads of rheumatoid arthritis, lupus, and vasculitis | Joint Bone Spine |
| 59 | 2017 |
| A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) | Annals of the Rheumatic Diseases |
| 249 | 2016 |
| Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease | Nature Medicine |
| 967 | 2016 |
Refrences Analysis
The category
Medicine: Medicine (General) 19
is the most frequently represented among the references in this article. It primarily includes studies from Journal of Immunology and Annals of the Rheumatic Diseases. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Tolerogenic probiotics Lactobacillus delbrueckii and Lactobacillus rhamnosus promote anti‐inflammatory profile of macrophages‐derived monocytes of newly diagnosed patients with systemic lupus erythematosus | Cell Biochemistry and Function |
| 2024 | |
| Identification of EPSTI1 as a new potential biomarker for SLE based on GEO database | Clinical Rheumatology |
| 2024 | |
| Systemic lupus erythematosus and Atopic dermatitis: A two sample Mendelian randomization study | Clinical Rheumatology |
| 1 | 2024 |
Helios characterized circulating follicular helper T cells with enhanced functional phenotypes and was increased in patients with systemic lupus erythematosus | Clinical and Experimental Medicine |
| 2024 | |
| Recent advances in the involvement of epigenetics in the pathogenesis of systemic lupus erythematosus | Clinical Immunology |
| 3 | 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 56
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled The Phenotype and Secretory Activity of Adipose-Derived Mesenchymal Stem Cells (ASCs) of Patients with Rheumatic Diseases and was published in 2019. The most recent citation comes from a 2024 study titled The role of innate lymphoid cells in systemic lupus erythematosus. This article reached its peak citation in 2023, with 62 citations. It has been cited in 114 different journals, 31% of which are open access. Among related journals, the Frontiers in Immunology cited this research the most, with 18 citations. The chart below illustrates the annual citation trends for this article.